Evolocumab is very safe—even when used for over 8 years and when cholesterol drops to extremely low levels, it doesn’t cause serious side effects, diabetes, or memory problems. The only common issue is mild redness or soreness where the shot is given.
Evidence from Studies
Supporting (1)
Community contributions welcome
The study looked at the same medicine, evolocumab, in similar patients and found it’s safe with only minor side effects at the injection site, just like the claim says.
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Provide the most comprehensive assessment of rare and long-term safety risks by pooling data across trials.
A systematic review and meta-analysis of all RCTs and long-term extensions of PCSK9 inhibitors, pooling adverse event data including diabetes, neurocognitive events, and injection site reactions, with at least 50,000 patient-years of exposure.
Establish causal safety profile with high internal validity.
A double-blind RCT of 30,000 ASCVD patients randomized to evolocumab vs placebo, with active monitoring for diabetes (HbA1c), cognitive function (standardized battery), and serious AEs over 5 years, with blinded adjudication.
Detect rare or long-latency adverse events in real-world use.
A prospective cohort study of 200,000 patients prescribed evolocumab in routine care, linked to national registries for diabetes, dementia, and hospitalizations, tracking outcomes over 10 years with propensity score matching.